Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Cercano Management LLC

Cercano Management LLC reduced its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 69.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,293 shares of the specialty pharmaceutical company’s stock after selling 12,038 shares during the quarter. Cercano Management LLC’s holdings in Jazz Pharmaceuticals were worth $1,225,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Bank of America Corp DE raised its stake in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares in the last quarter. Systematic Financial Management LP lifted its position in Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock worth $76,965,000 after purchasing an additional 10,237 shares during the period. Retirement Systems of Alabama grew its stake in Jazz Pharmaceuticals by 7.6% during the third quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company’s stock worth $39,775,000 after buying an additional 12,138 shares in the last quarter. Quantinno Capital Management LP grew its stake in Jazz Pharmaceuticals by 9.7% during the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock worth $36,163,000 after buying an additional 16,928 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its stake in Jazz Pharmaceuticals by 1.0% during the third quarter. Pictet Asset Management Holding SA now owns 149,115 shares of the specialty pharmaceutical company’s stock worth $34,640,000 after buying an additional 1,516 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on JAZZ. Barclays raised their target price on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Deutsche Bank upped their price target on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Citigroup assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price target on the stock. Royal Bank Of Canada increased their price target on shares of Jazz Pharmaceuticals from $296.00 to $305.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.25.

Check Out Our Latest Analysis on Jazz Pharmaceuticals

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $239.77 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.64 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $15.39 billion, a PE ratio of 21.31, a P/E/G ratio of 0.44 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 12 month low of $156.95 and a 12 month high of $266.38. The stock has a 50-day moving average price of $228.99 and a two-hundred day moving average price of $219.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the firm posted $8.13 earnings per share. Analysts expect that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Renée Galá sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total value of $486,060.00. Following the completion of the transaction, the chief executive officer owned 143,394 shares in the company, valued at $34,849,043.82. This trade represents a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,506,616.32. This represents a 17.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 171,342 shares of company stock worth $41,420,491 over the last quarter. 4.10% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Profile

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

See Also

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.